Cassava Sciences' shares dropped 13% after the SEC announced a $40 million settlement related to misleading claims about the results of a 2020 Phase II trial for its Alzheimer's drug, simufilam. The ...

Shares of Cassava Sciences, Inc (NASDAQ:SAVA) dropped 11.5% in pre-open trade on Friday following the company's statement that it has reached a $40 million settlement with the U.S. Securities and ...

Shares of Cassava Sciences, Inc. SAVA fell sharply in today's pre-market trading after the SEC charged the company, two ...

Cassava Sciences and its executives face a $40 million SEC settlement over manipulated data in an Alzheimer's drug trial, ...

Cassava Sciences shares fell in premarket trading Friday after regulators said the company, along with two former executives, will pay more than $40 million to settle charges related to misleading ...

Fidelity slashed the amount certain customers can deposit into their cash-management accounts to $1,000 from $100,000, people familiar with the matter said. The Boston firm is also subjecting some ...

Cassava Sciences settles SEC charges for $40M over misleading Alzheimer's drug trial results, ex-CEO and SVP also face negligence charges.

The U.S. Securities and Exchange Commission announced Cassava Sciences Inc. (SAVA), its founder and former CEO, Remi Barbier, and its ...

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...

The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug ...

Stocks rose Thursday, bolstered by positive economic data, and the S&P 500 nabbed another record close. Here’s what CNBC is ...